


AKSTON BIOSCIENCES PARTNERS WITH PURDUE FOR CANINE CANCER DRUG¹

Akston Biosciences has partnered with Purdue University to develop a promising anti-cPD-L1 monoclonal antibody aimed at treating cancer in dogs. This collaboration grants Akston the rights to license and produce the antibody, leveraging Purdue's cutting-edge research. Clinical trials are scheduled to start in late 2024, focusing on the drug's safety and effectiveness in treating bladder cancer in dogs. This partnership marks a significant step forward in veterinary oncology, with the potential to introduce a new, targeted treatment option for canine cancer.




VETERINARY DERMATOLOGY SECTOR TO NEARLY TRIPLE BY 2032²

The veterinary dermatology drug market is set to grow from \$7.1 billion in 2022 to nearly \$18 billion by 2032, driven by rising pet ownership, increased awareness of skin health, and advancements in treatments. Common conditions like allergies and skin infections are fueling demand, with topical therapies leading the market. Growth is particularly strong in North America and the Asia-Pacific region, supported by the expansion of veterinary services and clinics.




ORAL MICROBIOME KEY IN EARLY CANINE DENTAL DISEASE DETECTION³

A study by Waltham Petcare Science Institute reveals that the oral microbiome can help detect canine periodontal disease early. Using qPCR to analyze dental plaque, researchers achieved 80.9% accuracy in identifying disease-related bacteria. This method could lead to earlier, more accurate diagnoses, improving canine health outcomes.



FLOW CYTOMETRY EFFECTIVE IN CHARACTERIZING FELINE LYMPHOMA & PREDICTING SURVIVAL⁴

A recent study highlights the effectiveness of flow cytometry and clonality evaluation in characterizing feline lymphoma and predicting patient survival times. The research, conducted by ImpriMed, found that these methods are 82% concordant with traditional



cytology in diagnosing lymphomas in cats. The study revealed significant survival differences based on cell size: cats with small-cell lymphomas had a median survival of 312 days, medium-cell lymphomas 189 days, and large-cell lymphomas just 81 days. This new cell-sizing method offers valuable prognostic insights and could influence treatment decisions.

"Paws in the Park"

#BarkOutLoud was thrilled to participate in the 'Paws in the Park' event organized by Goodman Chemist on 15th August 2024 at Victoria South Venue, Mumbai. Our team was on the ground, passionately connecting with pet lovers and industry experts, and proudly showcasing our innovative products. The event was a great success, driven by our team's energy and commitment to making meaningful connections.

VIVALDIS CORNER




NEW PRODUCTS



Introducing
EFA Pet

Superior
OMEGA 3

IN PHOSPHOLIPID FORM



EFA Pet

